论文部分内容阅读
将HAb18-ADR-HSA-NP和ADR-HSA-NP或其131I标记物进行荷肝癌裸鼠实验,观察其在动物体内对肝癌细胞的靶向性及其抑瘤作用。结果表明:HAb18-ADR-HSA-NP的有效载药量为1.44%,比ADR-HSA-NP(1.69%)有所降低;呈缓慢释药状,其最大释药量(41%)明显低于ADR-HSA-NP(65%)(P<0.05)。正常裸鼠显像显示,131I-HAb18-ADR-HSA-NP在体内的趋肝性和稳定性均优于131I-ADR-HSA-NP,肝脏清除较131I-ADR-HSA-NP慢。HAb18-ADR-HSA-NP主要滞留于瘤体,随时间延长,其滞留量明显多于ADR-HSA-NP(P<0.05);它能明显抑制癌细胞生长,其抑癌率显著高于ADR-HSA-NP(P<0.05)。因此,HAb18-ADR-HSA-NP在体内能和肝癌细胞结合并抑制其生长。
The HAb18-ADR-HSA-NP and ADR-HSA-NP or their 131I markers were tested in nude mice bearing hepatocellular carcinoma to observe the targeting of HAb18-ADR-HSA-NP and ADR-HSA- The results showed that the effective drug loading of HAb18-ADR-HSA-NP was 1.44%, which was lower than that of ADR-HSA-NP (1.69%). On ADR-HSA-NP (65%) (P <0.05). Normal nude mice showed 131I-HAb18-ADR-HSA-NP had better hepatic stability and stability in vivo than 131I-ADR-HSA-NP and liver clearance was slower than 131I-ADR-HSA-NP. HAb18-ADR-HSA-NP mainly remained in the tumor, with more retention time than that of ADR-HSA-NP (P <0.05). It could significantly inhibit the growth of cancer cells and the tumor- -HSA-NP (P <0.05). Therefore, HAb18-ADR-HSA-NP binds to liver cancer cells in vivo and suppresses its growth.